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Objective: To compare the durations of response achieved with adjunctive vagus nerve 
stimulation (VNS + TAU) vs treatment as usual (TAU) alone in treatment-resistant depression 
(TRD) over a 5-year period in the TRD registry.
Materials and methods: Data from 271 participants on TAU and 328 participants on VNS + 
TAU were analyzed. Response was defined as 50% decrease in baseline Montgomery–Åsberg 
Depression Rating Scale (MADRS) score at postbaseline visit and was considered retained until 
the decrease was 40%. MADRS was obtained quarterly in year 1 and biannually thereafter. 
Time-to-events were estimated using Kaplan–Meier method and compared using log-rank 
test. HR was estimated using Cox proportion hazard model.
Results: In the VNS + TAU arm, 62.5% (205/328) of participants had a first response over 
5 years compared with 39.9% (108/271) in TAU. The time to first response was significantly 
shorter for VNS + TAU than for TAU (P0.01). For responders in the first year, median time to 
relapse from first response was 10.1 months (Q1=4.2, Q3=31.5) for VNS + TAU vs 7.3 months 
(Q1=3.1, Q3=17.6) for TAU (P0.01). HR=0.6 (95% CI: 0.4, 0.9) revealed a significantly 
lower chance for relapse in VNS + TAU. Probability of retaining first response for a year was 
0.39 (0.27, 0.51) for TAU and 0.47 (0.38, 0.56) for VNS + TAU. Timing of the onset of the 
response did not impact the durability of the response.
Conclusion: VNS therapy added to TAU in severe TRD leads to rapid onset and higher 
likelihood of response, and a greater durability of the response as compared to TAU alone.
Keywords: depressive disorder, treatment-resistant depression, vagus nerve stimulation, 
longitudinal study, durability of response
Introduction
Two major clinical challenges are encountered in the management of patients suffering 
from depression whether they are treatment resistant or not. First, there is the chal-
lenge of obtaining complete symptomatic remission in the acute treatment phase. With 
more failed treatments, the probability of remission in the acute phase decreases.1,2 
The second challenge focuses on the maintenance of the optimal symptomatic benefit 
once achieved in the acute treatment phase, that is, the prevention of relapse (a return 
of the current episode) or recurrence (onset of a new episode).3,4 The Sequenced 
Treatment Alternatives to Achieve Remission in Depression (STAR-D) trial found 
that relapse rates were higher in participants whose depression had failed to benefit 
adequately from a large number of prior acute phase treatment trials (ie, they were rated 
as having a greater level of “treatment resistance”).1 These two challenges – obtaining 
remission or at least a response, and then sustaining that benefit over time – are central 
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challenges in long-term depression management. This issue 
is even more pronounced in patients with higher levels of 
treatment resistance.
Vagus nerve stimulation (VNS) therapy entails the use 
of an implantable device in persons with severe treatment-
resistant depression (TRD).5,6 VNS is used as an adjunct 
or “add-on” treatment to ongoing medication treatment 
(typically antidepressant or mood stabilizing agents or other 
“augmenting” agents), in persons with TRD. The standard 
threshold for defining TRD in the VNS trials is failure of four 
adequate prior antidepressant treatments, although there is 
currently not a complete consensus on the required number 
of medication failures.7 Several reports have found either an 
earlier or more frequent benefit (in both response or remission 
rates) with VNS when added to treatment as usual (TAU) 
as compared to TAU alone.5,6,8,9 However, the appearance of 
symptom benefit is not realized for all participants within the 
first 3 months of initiating VNS.5,6,8
Most participants who responded during the pilot and 
pivotal VNS TRD studies showed durable clinical benefit.8,10–12 
For early responders, 63%–72% showed substantial clini-
cal benefit at 12 months, and these rates were 61%–77% at 
24 months. Likewise, 65%–79% of late responders showed 
substantial clinical benefit at 24 months.13 Berry et al found 
that for VNS + TAU, among participants who achieved 
response at 24 weeks as per the Montgomery–Åsberg 
Depression Rating Scale (MADRS), 153 (153/217=71%) 
had a sustained response at 48 weeks.9,14 Additionally, of 
the 104 participants in the VNS + TAU group evaluated at 
96 weeks, 70 (70/104=67%) had a sustained MADRS response.
None of the present publications have examined the 
long-term durability (up to 4 years) of the VNS-associated 
antidepressant responses and how a participant’s response 
is affected by the timing of the onset of the response (ie, 
do “early” responders stay well longer/shorter than “late 
responders”). Also, if participants lose their first response, 
what is the chance of achieving another response and how 
durable are those responses? We take advantage of a large, 
nonrandomized comparison between participants receiving 
treatment as usual (TAU) plus VNS as compared to those 
receiving TAU alone to answer these questions.6
aims of the study
We aimed to determine if duration of TRD first response was 
more sustained in patients receiving VNS + TAU vs TAU 
alone. We also aimed to determine if there is a correlation 
between the time at which the first response occurs and the 
durability of the response in the VNS + TAU treatment group. 
A third exploratory questions was also addressed: In those 
TRD patients who respond, and then subsequently relapse, 
do the two treatments groups differ in the likelihood of a 
second response, time to second response, or durability of 
the second response?
Materials and methods
study population
Participants were part of a Food and Drug Administration-
required registry of TRD patients followed for 5 years. 
The eligibility criteria for the TRD registry are detailed 
elsewhere.6,15 Briefly, participants had to be 18 years of age 
or older and experiencing a major depressive episode (MDE) 
of 2 years or longer in duration (either unipolar or bipolar 
depression) or have a history of at least three MDEs includ-
ing the current depressive episode and a life-time history of 
inadequate response to four or more adequate antidepressant 
treatments (dosage per Physicians’ Desk Reference labeling 
for a minimum of 4 weeks), which could include electrocon-
vulsive therapy (ECT). Participants could not have a history 
of psychotic disorder or rapid-cycling bipolar disorder, or 
psychotic features in the present MDE (ClinicalTrials.gov 
Identifier: NCT00320372).
study treatment
Before enrollment into the TRD registry, participants (except 
for VNS participants who were in the previously reported 
flexible dose study and were rolled over into the TRD registry 
study; note that these participants were excluded from the 
analysis in this article) were allowed to select the treatment 
arm of their choice.5 Some participants could be assigned to 
receive the alternate treatment by the site for various reasons, 
including availability of surgical implantation at a site, num-
ber of allocated slots for implantation, or failure to qualify 
for insurance reimbursement for VNS therapy implantation. 
Device implantation surgery and related medical care were 
covered either by a participant’s insurance policy or from 
personal funds.
Participants in the VNS + TAU arm underwent implanta-
tion during visit 2 (baseline). Postbaseline follow-up visits 
for all participants were conducted at 3, 6, 9, 12, 18, 24, 
30, 36, 42, 48, 54, and 60 months. Data were collected on 
medical status, adjustment of mood disorder therapy (as 
needed in the judgment of the clinician), concomitant treat-
ments (with no restrictions on concomitant treatments in 
this observational registry), and assessment of depressive 
symptom severity (MADRS, administered by offsite blinded 
central raters), as well as, the self-rated Quick Inventory of 
Depressive Symptomatology-Self Report and the Clinical 
Global Impression scale.16–18
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statistical analysis
Of the 494 participants in the VNS + TAU arm reported in 
Aaronson et al, 159 participants who had “crossed over” 
from VNS treatment in the previously reported flexible dose 
study were excluded, as most of these subjects had only 
1 year of consistent follow-up data and our study aimed to 
understand long-term retention of the response.5,6 In addi-
tion, the analysis excluded participants who had a baseline 
MADRS score of 10 as it indicated that they were already 
remitted from their MDE prior to initiation of treatment; this 
excluded n=2 from VNS + TAU and n=5 from TAU alone.19 
After the above exclusions and then only including the par-
ticipants in the intention-to-treat population yielded a total of 
328 participants in VNS + TAU group and 271 participants 
in TAU group. Note that participants who were crossed over 
to another arm during the study were censored at the last visit 
before crossover.
analyses
A time-to-event analysis was conducted for the data as 
follows:
•	 Time to first response was defined as the time from 
baseline to the first visit with reduction in MADRS score 
of 50% compared to baseline. Note that similar analysis 
was done in Aaronson et al.6 However, since our sample is 
different, we repeated the analysis to understand whether 
trend observed in Aaronson et al is maintained in this 
sample.6
•	 Duration of first response as per MADRS was defined as 
the time from first response to the first visit when reduc-
tion in MADRS score was 40% compared to baseline. 
Similar to Sackeim et al, the criterion for maintenance 
of response at the follow-up time points was reduced to 
an improvement of at least 40% relative to baseline to 
avoid characterizing a minor decrease (eg, from 51% to 
49%) as loss of benefit.13 A MADRS score drop of 40% 
constituted a clinically meaningful loss of treatment 
response, hereafter called “relapse”. Note that only par-
ticipants who achieved first response within the first year 
of starting treatment in the registry were included in this 
analysis. These participants could have potentially been 
followed-up for 4 years and hence provided a reasonable 
sample to assess the long-term durability of first response.
•	 Time to second response was the time from the first 
relapse to the subsequent visit when reduction in MADRS 
score was 50% compared to baseline. This analysis was 
conducted only for those participants who responded 
within the first year and had relapsed after their initial 
response.
•	 Duration of second response was defined as the time from 
a second response to a visit when reduction in MADRS 
score was 40% compared to baseline. Only first year 
responders who relapsed from their first response and 
had a second response were included in this analysis.
For all the above data, a probability of time to event was 
estimated using Kaplan–Meier (KM) method. KM plots 
along with the number of participants at risk at periodic time 
points are provided. KM probability estimates for the time to 
event with 95% CI at month 3, 6, 9, and 12 are provided. Time 
to event curves for the two treatment arms were compared 
using log-rank test. A Cox proportion hazards model was 
used to estimate the HR (and 95% CI) of the instantaneous 
chance of a participant having an event in the VNS + TAU 
arm compared to the TAU arm, at any given time during 
follow-up.
We evaluated the impact of the timing when the first 
response occurred (eg, at 3-, 6-, 9-, or 12-month visits) on 
the durability of first response for the VNS + TAU arm. 
A KM plot for the time to relapse from the first response 
(that occurred in first year) is provided by visit when first 
response occurred.
Missing data imputation
We imputed one or two consecutive missing data with the 
average of the two adjacent nonmissing data. No imputa-
tion was done for three or more consecutive missing data. 
After imputation, participants were censored at the last 
visit with nonmissing data for all the analysis. Thus, we 
had total 2,343 visits with data for TAU participants and 
2,991 visits with data for VNS + TAU participants in the 
censored data set. Imputation for a single missed data point 
in the censored data set was done for 146 visits (146/2,343, 
ie, 6.2% of all available data) for TAU participants and for 
199 visits (199/2,991, ie, 6.7% of all available data) for 
VNS + TAU participants. Imputation for two consecutive 
missing data points was done for 82 visits (82/2,343, ie, 
3.5% of all available data) for TAU participants and for 
106 visits (106/2,991, ie, 3.5% of all available data) for 
VNS + TAU participants. Overall there were 228 imputed 
data (228/2,343, ie, 9.7% of all available data) in TAU arm 
and 305 imputed data (305/2,991, ie, 10.2% of all available 
data) in VNS + TAU arm.
The imputation method maintains the pattern of response 
status regardless of what threshold is used to define a new 
response or maintenance of a response. That is, if a patient 
has a response at the adjacent visits then the imputation will 
give a response at the missed visit. Similarly, if a patient had 
no response at the adjacent visits, then the imputation will 
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give a no-response at the missed visit. Only when responses 
are different at the adjacent visits then an imputed response 
at a missed visit could thus have prolonged a response main-
tenance (if pattern is [response, missed visits, no-response]) 
or could have given an earlier response (if pattern is [no-
response, missed visits, response]). Otherwise imputation 
favors only the treatment arm that has more missing data 
with adjacent responses, which is indeed desirable.
We provide additional summary below about the 
imputed censored data set to show that imputation could 
not have altered the result substantially in favor of any of 
the treatment arms unless a treatment arm has more miss-
ing data with adjacent responses. When response is defined 
as reduction of MADRS score of 50%, the censored data 
set has a regular response pattern, ie, either response or no-
response at both the adjacent visits around the one missing 
data 74.7% for TAU and 62.3% for VNS + TAU, and around 
two consecutive missing data 90.2% for TAU and 86.8% for 
VNS + TAU. Thus, occurrence of first or second response 
could have been altered due to imputation, only for 1.91% 
of the censored data for TAU arm and 2.97% of censored 
data in VNS + TAU arm. Similarly, when response is defined 
as reduction of MADRS score of 40%, the censored data 
set provided a regular response pattern around one missing 
data 67.1% for TAU and 55.3% for VNS + TAU, and around 
two consecutive missing data 85.4% for TAU and 81.1% for 
VNS + TAU. Thus, prolongation of the response maintenance 
could have occurred only for 3.49% of the censored data in 
VNS + TAU arm and 2.56% of the censored data in the TAU 
arm. Given the small percentage of data that could have an 
altered response pattern due to imputation and noting that 
not all alterations in the response pattern are favorable, we 
conclude that the imputation method would work reasonably 
well for this data set.
Results
sample demographics and disease 
characteristics
The analysis population included 328 participants in the 
VNS + TAU arm and 271 participants in the TAU arm. Base-
line demographic characteristics and clinical information for 
the analysis population are provided in Table 1.
Table 1 Baseline demographic characteristics and clinical features of participants with treatment-resistant depression receiving TaU 
with or without adjunctive VNs + TaU (two-sided t-test P-value for continuous data and asymptotic normal test P-value for categorical 
data)
VNS + TAU (N=328) TAU (N=271) P-value
Mean or N SD or % Mean or N SD or %
age (years) 48.8 10.37 50.0 10.80 0.168
Number of female subjects 225 68.6 192 70.8 0.612
Number of white subjects 318 97.0 246 90.8 0.002
age at initial onset of depression (years) 20.8 12.12 21.4 11.54 0.536
age at initial diagnosis of depression (years) 29.0 10.90 29.7 11.67 0.451
Number of failed treatments for depression 8.0 3.04 7.4 2.93 0.014
lifetime number of diagnosed depressive episode 15.1 24.34 11.7 24.56 0.090
Psychiatric hospitalizations within prior 5 years 2.8 4.63 1.5 2.87 0.001
lifetime suicide attempts 2.0 4.35 1.2 2.32 0.004
history of electroconvulsive therapy 191 58.2 107 39.5 0.001
DsM-iV-Tr primary diagnosis
Moderate recurrent major depression 40 12.2 66 24.4 0.001
severe recurrent major depression 133 40.5 85 31.4 0.025
Moderate single-episode major depression 12 3.7 29 10.7 0.001
severe single-episode major depression 46 14.0 32 11.8 0.496
Bipolar i, currently moderately severe major depressive episode 19 5.8 18 6.6 0.795
Bipolar i, currently severe major depressive episode 46 14.0 10 3.7 0.001
Bipolar ii, currently depressed 32 9.8 31 11.4 0.592
Baseline scores
Montgomery–Åsberg Depression rating scale 33.2 7.67 29.5 6.40 0.001
clinical global impressions-severity 5.2 0.78 4.7 0.72 0.001
Quick inventory of Depressive symptomatology-self report 18.3 4.67 15.8 4.92 0.001
Abbreviations: TaU, treatment as usual; VNs, vagus nerve stumulation.
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1. In persons with TRD, does VNS + TAU differ from TAU 
alone in regard to the onset of response (defined by at least 
a 50% reduction in baseline MADRS) and cumulative 
response rate over time?
In a similar data set, VNS + TAU demonstrated greater 
cumulative first onset of antidepressant response.6 A similar 
analysis was performed here to confirm if the trends are 
maintained in this sample. Overall, 62.5% (205/328) of par-
ticipants in the VNS + TAU arm had a first response during 
the entire follow-up, compared to 39.9% (108/271) of partici-
pants in the TAU arm. The KM plot of time to first response 
shows that the time to first response was significantly shorter 
for VNS + TAU than for TAU alone (P0.01 for log-rank 
test) (Figure 1) and the estimated cumulative probability for 
the time to first response is higher for VNS + TAU partici-
pants compared to TAU participants over the majority of the 
follow-up period (Table 2). Median time to the first response 
was 18.1 months (Q1=6.9, Q3=49.1) for VNS + TAU par-
ticipants compared to 49.1 months (Q1=12.3, Q3=not esti-
mable) for TAU participants. HR for time to first response 
for VNS + TAU compared to TAU was 2.0 (95% CI: 1.6, 
2.5) meaning a statistically significantly larger chance for a 
VNS + TAU participant to get a first response compared to 
TAU participants at any given time during the follow-up.
2. In individuals who achieve a first response, does VNS + 
TAU differ from TAU alone in regard to the duration of 
the response (defined a priori as maintenance of at least 
a 40% reduction from baseline MADRS)?
A total of 148 (148/205=72.2%) participants had a 
first response in the first year in VNS + TAU arm and 69 
(69/108=63.9%) participants had a first response in first 
year in the TAU arm. Of the 148 in the VNS + TAU arm, 
98 (98/148=66.2%) participants relapsed from their first 
response during the study. Out of the 69 participants with 
first response in first year in the TAU arm, 55 (55/69=79.7%) 
participants relapsed from first response during the study. 
KM plot of time to relapse from first response demonstrates 
significantly longer time to relapse for the VNS + TAU 
arm (P0.01 for log-rank test) (Figure 2). When response 
occurred within the first 12 months of initiating treatment, 
time to relapse took 1 year or longer for 47% of the respond-
ers in VNS + TAU, compared to 39% of the responders in 
TAU (Table 2). Median time to relapse from first response 
in first year was 10.1 months (Q1=4.2, Q3=31.5) for 
VNS + TAU and 7.3 months (Q1=3.1, Q3=17.6) for TAU. 
HR for time to relapse for VNS + TAU compared to TAU 
was 0.6 (95% CI: 0.4, 0.9) indicating a significantly lower 
probability for VNS + TAU participants to lose response 
compared to TAU participants at any given time during 
the follow-up.
3. In VNS + TAU group, is the time at which the first 
response occurs related to the durability of that response?
0 6 12 18 24 30 36 42 48 54 60 66
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Figure 1 A Kaplan–Meier plot demonstrates time to first response among 328 participants in the VNS + TaU group and 271 participants in the TaU group.
Notes: Time to first response was defined as the time from baseline to the first visit with a reduction in MADRS score of 50% compared to baseline. Median time to the 
first response was 18.1 months (Q1=6.9, Q3=49.1) for VNs + TaU participants compared to 49.1 months (Q1=12.3, Q3= not estimable) for TaU participants.
Abbreviations: MaDrs, Montgomery–Åsberg Depression rating scale; TaU, treatment as usual; VNs, vagus nerve stimulation.
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In VNS + TAU group, the probability of retaining the 
first response beyond 1 year is higher in early responders 
(those who first responded at 3 or 6 months visits) than 
in late responders (those who first responded at 9 or 
12 months) although the sample size is not sufficient to 
make any definite conclusion (P≈1.00 for log-rank test) 
(Figure 3). We conducted similar analysis putting early 
responders (3 or 6 months) as one group and late responders 
(9 or 12 months) as another group. Pattern was similar 
(Figure S1) (P=0.06).
4. In each treatment group, does VNS + TAU differ from 
TAU alone in regard to the onset of a second response for 
participants that has relapsed from first response? How 
does VNS + TAU differ from TAU in terms of retaining 
a second response?
There is a substantial chance of a second response after 
the first response in both the TAU and VNS + TAU groups 
(Figure S2; Table 2). The two treatment arms do not differ 
significantly in the timing or overall likelihood of having a 
second response as measured from the time when the first 
Table 2 Kaplan–Meier probability estimates with 95% ci
Probability of first response over time
3 months 6 months 9 months 12 months
TaU 0 (0, 0.03) 0.10 (0.07, 0.15) 0.19 (0.15, 0.24) 0.24 (0.19, 0.30)
VNs + TaU 0.01 (0, 0.03) 0.22 (0.17, 0.27) 0.33 (0.28, 0.38) 0.42 (0.36, 0.47)
Probability of retaining the first response (response durability) over time
TaU 0.75 (0.63, 0.84) 0.58 (0.45, 0.69) 0.41 (0.29, 0.53) 0.39 (0.27, 0.51)
VNs + TaU 0.85 (0.78, 0.9) 0.65 (0.57, 0.73) 0.52 (0.43, 0.6) 0.47 (0.38, 0.56)
Probability of second response over time following relapse from the first response
TaU 0 0.13 (0.06, 0.27) 0.27 (0.16, 0.43) 0.32 (0.20, 0.48)
VNs + TaU 0.07 (0.04, 0.15) 0.26 (0.18, 0.36) 0.44 (0.35, 0.55) 0.47 (0.37, 0.58)
Probability of retaining second response (response durability) over time
TaU 0.97 (0.79, 1) 0.82 (0.63, 0.92) 0.63 (0.42, 0.78) 0.46 (0.27, 0.64)
VNs + TaU 0.98 (0.89, 1) 0.89 (0.78, 0.95) 0.73 (0.59, 0.82) 0.66 (0.52, 0.77)
Abbreviations: TaU, treatment as usual; VNs, vagus nerve stimulation.
Figure 2 A Kaplan–Meier plot for durability of the first response that occurred within the first year.
Notes: Duration of first response was defined as the time from first response to the first visit when reduction in MADRS score was 40% compared to baseline (ie, relapse). 
Median time to relapse from first response in first year was 10.1 months (Q1=4.2, Q3=31.5) for VNs + TaU and 7.3 months (Q1=3.1, Q3=17.6) for TaU.
Abbreviations: MaDrs, Montgomery–Åsberg Depression rating scale; TaU, treatment as usual; VNs, vagus nerve stimulation.
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response was lost. Thus, VNS neither increases nor appar-
ently decreases the chances of the second response. However, 
more participants initially responded to VNS + TAU. Thus, 
achieving a second response is presumably occurring in at 
least some participants whose depression would be unlikely 
to respond to TAU alone.
The durability of the second response when it occurs 
with VNS + TAU may be more durable than the second 
response to TAU alone (P=0.06) (Figure S3; Table 2). The 
analysis is limited by sample sizes. However, it indicates 
that VNS has no obvious negative effect in the durability of 
the second response.
Discussion
In this nonrandomized comparative study of participants 
with either bipolar depression (30%) or unipolar depression 
with very substantial levels of treatment resistance, we found 
that symptomatic response defined by the MADRS was 
about twice as likely in those who received VNS + TAU 
as compared to TAU alone at 1-year postimplant. For those 
who responded, the duration of that benefit was significantly 
longer for those who received VNS + TAU than for those 
in TAU alone. At 12 months after the initial response, 47% 
of those who had responded to VNS + TAU still retained 
their response, compared to 39% of responders to TAU. 
Furthermore, there were suggestive (but not statistically 
significant) indications that those who achieved an earlier 
depression symptom benefit were more likely to sustain that 
benefit for at least 1 year.
Results also revealed that in both VNS + TAU and TAU 
groups, when a response was lost, a second response did 
occur for a substantial percentage of participants within 
12 months after losing the initial response. Approximately 
half of the participants in the VNS + TAU group, as compared 
to about 1/3 of those in the TAU, had their second response 
within 12 months. There was no statistically significant dif-
ference between the two groups in the probability or timing 
of onset of achieving a second response. When this second 
response did occur, it may have been more durable for those 
treated with VNS + TAU than for TAU alone – persisting 
for at least 12 months for 66% in the VNS + TAU group vs 
46% for TAU alone. However, these percentages are not 
statistically different.
This is the first study to look at the long-term durabil-
ity of benefit up to 4 years, defined here as response based 
on 50% reduction in baseline MADRS score to declare the 
Figure 3 A Kaplan–Meier plot for durability of first response in the first year for VNS + TaU participants by visit.
Note: The trend in the probability of retaining the first response beyond 1 year was higher in the early responders (ie, those who first responded at 3 or 6 months after 
VNS initiation) compared with the late responders (ie, those who first responded at 9 or 12 months after VNS initiation).
Abbreviations: TaU, treatment as usual; VNs, vagus nerve stimulation.
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onset of response and a threshold of retaining at least a 40% 
reduction compared to baseline to retain the response. As 
expected from prior reports, the probability and timing of 
first response were more likely to be sooner with adjunctive 
VNS treatment than with TAU alone. In terms of long-term 
durability, VNS + TAU participants are expected to retain 
their response longer than TAU participants (HR=0.6, 95% 
CI: 0.4, 0.9).6 Similar to prior reports, a substantial propor-
tion (about 50%) of participants who achieved a response 
maintained that benefit for at least a year after the response 
began.9,13,20 In addition, while half of these participants lost 
this initial response, half achieved a second response in 
12 months. Furthermore, with adjunctive VNS, the second 
response was retained in two out of three participants for an 
additional 12 months.
The durability of response in this cohort was somewhat 
lower than expected from the previous pilot studies and ran-
domized controlled trials.8,21 Possible explanations include 
the following: 1) these participants were treated under general 
clinical conditions not managed by research staff and 2) the 
sample contained 30% with bipolar depression whereas the 
other samples generally included about 10%–15% of bipo-
lar depressed participants. A greater waxing and waning of 
symptoms would be expected from the bipolar sample. This 
issue was examined in our sample and we found no differ-
ence in response between participants diagnosed with bipolar 
depression vs unipolar depression (Figure S4). The present 
data also indicate that VNS is not impairing participant’s 
ability to achieve a second response following an initial 
response and subsequent relapse.
Comparison of the durability of the first response in this 
TRD sample is challenging due to sample size limitations 
and to the fact that any comparison between these treatment 
arms is contingent on a response having occurred. That is, 
we are comparing only those who responded in each arm. 
VNS + TAU produced more responders even though they 
likely included more difficult-to-treat (poorer prognosis) 
depressions that are at greater risk of relapse (ie, are not able 
to sustain a benefit once it occurs). Despite this likely bias 
against VNS + TAU in these two responder samples, the 
HR of 0.6 (95% CI: 0.4, 0.9) reveals a significantly smaller 
chance of loss of response for a VNS + TAU responder than 
for a responder in TAU.
Another benchmark by which to evaluate the present 
results is the Level 4 STAR-D participants all of whom had 
failed on three prior well-delivered medication treatments.1 
While the acute trial was only 12 weeks in the fourth step, 
the remission rate was 15% and the response rate was not 
much greater. Of those who entered follow-up, most had 
responded but had not achieved remission prior to entering 
follow-up. Their relapse rate was over 80% over 12 months, 
which is substantially greater than the roughly 45% 12-month 
relapse rate for VNS + TAU participants and roughly 65% 
relapse rate for TAU participants.
limitations
This study has several limitations: the two groups were not 
randomized, although majority of their clinical characteristics 
were comparable. In fact, the higher rate of prior ECT treat-
ment (58% in VNS + TAU compared to 40% in TAU arm) 
and the higher proportion of severe recurrent major depres-
sion in VNS + TAU would suggest that the VNS + TAU 
group was more severely ill. In addition, there was no control 
for treatment. That is, we cannot conclude with certainty that 
all the observed effects were exclusively related to adjunctive 
VNS treatment. In this effectiveness trial, medications and 
other treatments, such as TMS and ECT, could change for 
the participants in both treatment arms though Conway et al 
(2018) mentioned unpublished results that showed that there 
were more medication changes in the TAU group. Thus, it is 
unlikely that benefits seen for VNS + TAU patients were due 
to other therapies.22 Furthermore, participants and clinicians 
were knowledgeable about the care being given. However, 
the off-site central raters collecting the MADRS were blind 
to both treatment arm and overall clinical status. The partici-
pant population limits generalizability, though it is of course 
reasonably representative of participants suffering from TRD. 
Finally, in this 5-year longitudinal study, participant attrition 
over time limits our ability to address with sufficient sample 
sizes some of the questions posed. The primary reasons for 
attrition did not fall in an identifiable category and hence was 
collected in the database under category “Others”. The next 
two significant reasons for attrition were consent withdrawal 
and noncompliance.
Conclusion
Persons with severe TRD who are treated with adjunctive 
VNS have a reasonable probability of achieving response 
within the first year (42%). Of those responders, VNS + 
TAU participants retain response longer compared to TAU 
participants; close to 50% can expect to retain that benefit 
over the subsequent 12 months. For those who lose that 
benefit, the chances of a second response are on the order of 
50% within the subsequent 12 months and when a second 
response occurs, two-thirds in VNS + TAU and less than 
half in TAU can expect to retain it for the subsequent year.
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Figure S1 A Kaplan–Meier plot for durability of first response in the first year for VNS + TaU participants by early and late responder.
Note: The trend in the probability of retaining the first response beyond 1 year was higher in the early responder group (ie, first response at 3 or 6 months after VNS 
initiation) compared with the late responder group (ie, first response at 9 or 12 months after VNS initiation).
Abbreviations: TaU, treatment as usual; VNs, vagus nerve stimulation.
Supplementary materials
??????????? ?????????????????????
????????????
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Figure S2 A Kaplan–Meier plot shows the chance of a second response after relapse following the first response within the first year in both VNS + TaU and TaU.
Abbreviations: TaU, treatment as usual; VNs, vagus nerve stimulation.
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Figure S3 a Kaplan–Meier plot demonstrates that the second response may be more durable with VNs + TaU versus TaU.
Abbreviations: TaU, treatment as usual; VNs, vagus nerve stimulation.
Figure S4 a Kaplan–Meier plot demonstrates that there was no difference in durability of the response in either treatment group based on the polarity of the depression.
Abbreviations: TaU, treatment as usual; VNs, vagus nerve stimulation.
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